BLUESTAR ADISSEO COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.27 CNY | -2.52% |
|
+0.76% | +15.88% |
| 04-25 | Bluestar Adisseo Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-22 | Elkem Names New Chair of the Board | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The firm trades with high earnings multiples: 29.4 times its 2024 earnings per share.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +15.88% | 3.43B | B- | ||
| -19.73% | 72.39B | B+ | ||
| -11.01% | 6.54B | B- | ||
| -2.92% | 3.12B | B- | ||
| -0.68% | 1.4B | - | ||
| -17.27% | 1.34B | B | ||
| -2.73% | 1.26B | - | ||
| -14.67% | 1.12B | - | ||
| -5.37% | 990M | - | ||
| -24.06% | 805M | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600299 Stock
- Ratings Bluestar Adisseo Company
